SimpleFunctions
Winner-take-all answer·5 source contracts·Kalshi 5·refreshed just now·Closes Jul 1, 2026 · 5d

Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report No Results Phase 3 results in SAM-002

Leader sits at 66% across 5 bound outcomes, runner-up at 18%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

66%

No Results

runner-up 18¢leader 66¢

Outcomes

5

winner-take-all

Runner-up

18¢

Success

Spread

48pp

contested

24h volume

$86

thin orderbook

Closes

Jul 1, 2026

5 days

Venue

Kalshi

5 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayNo Results: 66% (12 days, 5 points)No Results: 66% on 2026-06-20Success: 21% (12 days, 10 points)Success: 21% on 2026-06-24Mixed: 4% (12 days, 4 points)Mixed: 4% on 2026-06-25
No Results66¢Success21¢Mixed4¢
Top 3 candidates by current price · 12d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Analysis

This market reflects a 65% probability that Samson Clinical Operations' sublingual minoxidil treatment for male hair loss will report inconclusive or unsuccessful Phase 3 results in the SAM-002 trial. The high probability of negative or ambiguous outcomes suggests market participants assign meaningful risk to the drug failing to demonstrate efficacy sufficient for regulatory approval. Current market pricing is driven by baseline skepticism about sublingual minoxidil as a novel delivery mechanism for a known compound, though limited recent clinical data appears publicly available. The resolution hinges on when Samson reports Phase 3 trial results, which would definitively establish whether the formulation met its primary efficacy endpoints. This matters because positive results would represent a new treatment option for androgenetic alopecia, while negative results would redirect the company's development priorities.

  • Sublingual minoxidil is a reformulation of an existing compound; market may be pricing in difficulty demonstrating meaningful advantage over established topical delivery
  • Phase 3 trial design specifics (primary endpoints, patient population, comparator choice) would significantly influence outcome probability if disclosed
  • Absence of publicly available interim data or recent company updates may reflect either deliberate information control or lack of compelling preliminary signals
  • Timeline to results announcement remains undefined; extended timelines without updates typically correlate with lower success probability in biotech markets
  • Competitor landscape and regulatory precedent for other novel hair-loss formulations could shift probability if new approvals or failures occur

What moved the line

  • Jun 18Mixed4pp26¢ · Kalshi
  • Jun 19Failure4pp62¢ · Kalshi
  • Jun 24Success3pp1821¢ · Kalshi

Recently closed in oil

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Other questions in oil.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: just now.